Baupost Group LLC MA Purchases 160,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Baupost Group LLC MA grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 23.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 833,696 shares of the specialty pharmaceutical company's stock after buying an additional 160,000 shares during the period. Jazz Pharmaceuticals accounts for approximately 2.2% of Baupost Group LLC MA's holdings, making the stock its 12th biggest position. Baupost Group LLC MA owned 1.32% of Jazz Pharmaceuticals worth $102,545,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Captrust Financial Advisors increased its position in shares of Jazz Pharmaceuticals by 2.4% during the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company's stock valued at $577,000 after purchasing an additional 86 shares during the last quarter. First Republic Investment Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 0.7% in the fourth quarter. First Republic Investment Management Inc. now owns 12,062 shares of the specialty pharmaceutical company's stock worth $1,922,000 after buying an additional 88 shares during the period. Daiwa Securities Group Inc. boosted its position in shares of Jazz Pharmaceuticals by 2.5% in the third quarter. Daiwa Securities Group Inc. now owns 4,076 shares of the specialty pharmaceutical company's stock worth $528,000 after purchasing an additional 100 shares during the period. Utah Retirement Systems boosted its holdings in Jazz Pharmaceuticals by 0.9% in the 4th quarter. Utah Retirement Systems now owns 10,836 shares of the specialty pharmaceutical company's stock worth $1,726,000 after buying an additional 100 shares during the period. Finally, Waterfront Wealth Inc. grew its position in shares of Jazz Pharmaceuticals by 1.2% during the fourth quarter. Waterfront Wealth Inc. now owns 8,633 shares of the specialty pharmaceutical company's stock worth $1,062,000 after purchasing an additional 103 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Philip L. Johnson bought 12,000 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the purchase, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at approximately $3,342,063.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson purchased 12,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was purchased at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the transaction, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the business's stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on JAZZ shares. HC Wainwright reduced their price objective on Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating on the stock in a research note on Thursday, March 14th. Cantor Fitzgerald reissued an "overweight" rating and set a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, March 22nd. Truist Financial reaffirmed a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Stifel Nicolaus boosted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a "buy" rating in a research report on Friday, March 15th. Finally, Robert W. Baird initiated coverage on Jazz Pharmaceuticals in a research note on Wednesday, January 3rd. They set an "outperform" rating and a $160.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $195.08.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ traded down $1.33 during trading hours on Monday, reaching $115.09. 437,763 shares of the company were exchanged, compared to its average volume of 615,383. Jazz Pharmaceuticals plc has a twelve month low of $111.25 and a twelve month high of $147.45. The company has a current ratio of 2.24, a quick ratio of 1.85 and a debt-to-equity ratio of 1.37. The stock's 50-day moving average is $122.06 and its 200-day moving average is $123.63. The firm has a market cap of $7.25 billion, a PE ratio of 18.81, a price-to-earnings-growth ratio of 1.61 and a beta of 0.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.44 by ($0.04). The company had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.